Objective. To investigate HRPT2 in jaw ossifying fibroma (OF), fibrous dysplasia (FD), and osteosarcoma (OS). Study Design. We combined microsatellite loss of heterozygosity (LOH), HRPT2 sequence alterations at the mRNA level by reverse-transcription polymerase chain reaction (PCR), cDNA sequencing, and quantitative PCR (qPCR) and immunohistochemistry (IHC) in a total of 19 OF, 15 FD, and 9 OS. Because HRPT2 (parafibromin) interacts with cyclin D1, we investigated cyclin D1 expression with the use of qPCR and IHC. Results. LOH was detected in 3/5 FD, 6/9 OF, and 2/2 OS heterozygous samples. LOH was not associated with decreased mRNA levels or HRPT2 protein expression except for 1 OF which harbored an inactivating mutation. However, this tumor did not display altered transcription or protein levels of HRPT2 nor cyclin compared with the other OF. Conclusions. The contribution of HRPT2 inactivation to the pathogenesis of OF, FD, and OS is marginal at best and may be limited to progression rather than tumor initiation.
Fibrous dysplasia (FD) and ossifying fibroma (OF) are benign fibro-osseous lesions that can affect the maxillofacial bones [1] [2] [3] and are characterized by bone replacement with cellular fibrous tissue containing foci of mineralization that vary in amount and appearance. 4 The molecular mechanisms involved in the pathogenesis of these benign lesions are for the most part unknown. FD has been associated with somatic postzygotic activating mutations in the GNAS1 gene, 5, 6 supporting earlier studies that suggested that FD is a monoclonal lesion. 7, 8 However, most clonality studies were based on X chromosome inactivation assays, which for the most part did not consider tumor heterogeneity and the existence of several subclones in the tumor tissue. 9, 10 Indeed, the GNAS-activating mutation has been shown to exist in a mosaic pattern in anatomically distinct regions of the same tumor, a finding that further supports oligoclonality of this tumor type. 11, 12 Unlike FD, clonality of OF has never been reported in peerreviewed journals.
OS is a malignant bone tumor, rare in the head and neck regions, whose exact underlying molecular mechanisms remain elusive. Somatic genetic alterations have been reported in this tumor type, and notably, germline mutations in the Rb and P53 genes are associated with an increased lifetime risk for developing this tumor. 13, 14 The HRPT2 tumor suppressor gene localizes to 1q24-32 and encodes for a 531-amino acid-long protein, called parafibromin, that exerts some of its antiproliferative activities via interaction with cyclin D1. 15, 16 Germline mutations and somatic inactivation of HRPT2 are associated with hyperparathyroidismjaw tumor syndrome (HPT-JT; OMIM #145001), a tumor predisposition syndrome characterized by parathyroid tumors, benign fibro-osseous lesions (BFOL) of the mandible and maxilla, renal cysts, and Wilms tumor. [15] [16] [17] [18] [19] [20] [21] Our group previously described germline and somatic mutations of HRPT2 in 2/3 OF. 22 Given some similarities in histologic features and anatomic location, we hypothesized that HRPT2 may also be in-volved in the pathogenesis of other related jaw lesions-FD and osteosarcoma (OS). In addition, we aimed at defining the extent that this gene is involved in seemingly sporadic OF.
MATERIALS AND METHODS

Tumors analyzed-identification and recruitment
A total of 15 FD, 19 OF, and 9 OS samples was evaluated in the study, including 6 FD, 10 OF, and 2 OS fresh human tumor samples. Seven normal bone samples from third molar extractions with no clinical evidence of inflammation or neoplasm were also collected. The study was approved by the Ethics Committee of the Universidade Federal de Minas Gerais, and each of the participants gave informed consent. Four OF cases had already been included in a previous study. 22 In addition to the freshly collected and analyzed lesions, 9 FD and 9 OF were also selected from the files of the Oral Pathology Service of Universidade Federal de Minas Gerais and 7 OS from the files of the Pathology Division, Centro Clinico de Cabeza y Cuello/Hospital Herrera-Llerandi, Guatemala, to be included in the immunohistochemistry analyses. These paraffin-embedded samples were obtained after informed consent and with the approval of the local Ethics Committees.
Tumor and control tissue processing
A portion of each fresh lesion and control sample was stored in RNA Holder (Bioagency Biotecnologia, São Paulo, SP, Brazil) at Ϫ80°C, and another part was stored in 10% buffered formalin and paraffin embedded for hematoxylin and eosin (HE) staining and immunohistochemistry (IHC). The precise diagnosis of each tumor type was based on clinical, radiographic, surgical, and histologic features as described elsewhere. 4, 23, 24 All OF were conventional, except 1 case that was a juvenile OF and 1 case that was associated with HPT-JT. These 2 nonconventional OF are listed in Table I . digested with proteinase K, and the genomic DNA was extracted with the use of the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). DNA was amplified with ␤-globin as an internal control. Loss of heterozygosity (LOH) was assessed with the use of 2 polymorphic DNA markers located in the long arm of chromosome 1, D1S384 (1q25.3) and D1S461 (1q25.3), flanking HRPT2. Marker positions and their relation to the HRPT2 locus are illustrated in Figure 1 . Fluorescent-labeled primers and PCR conditions were used as previously described. 25 Amplification products were detected with the use of an ABI Prism 310 (Applied Biosystems, Foster City, CA, USA), and data were analyzed with the use of Genemapper software version 3.0 (Applied Biosystems,). Normal microdissected tissue was first evaluated for informative status (i.e., heterozygosity) for each marker. Homozygous normal tissue markers were considered to be noninformative. Alleles were assessed as being in balance when the ratio of the individual allele peaks fell within the range of Ͻ0.66 or Ͼ1.50. 26 LOH was calculated as previously described by van Houten et al. (2000) .
DNA isolation and microsatellite analysis
27
Parafibromin and cyclin D1 immunohistochemistry Tissue sections from 14 FD, 18 OF, and 9 OS were immunostained with parafibromin and cyclin D1 antibodies. Parafibromin expression was evaluated with the use of a murine monoclonal antibody that targets the peptide corresponding to amino acid 87-100, encoded by exon 3 of HRPT2 (sc-33638; Santa Cruz Biotechnology, Santa Cruz, CA, USA). 28 Briefly, deparaffinized 4-m sections were steamed in citrate buffer (pH 6) for 30 minutes. Then, endogenous peroxidase activity was blocked with 10% H 2 O 2 in methanol for 10 minutes. The parafibromin antibody was diluted at 1:200 and the cyclin D1 (clone DCS-6; Dako, Golstrup, Denmark) at 1:100 and incubated for 30 minutes at room temperature. Sections were incubated in Envision ϩ Dual Link System-horseradish peroxidase (Dako, Carpinteria, CA, USA) for 30 minutes at room temperature, and reactions were revealed with 3,3=-diaminobenzidine (Sigma, St. Louis, MO, USA) with timed monitoring using a positive control sample (oral squamous cell carcinoma with known reactivity). The sections were then counterstained with Mayer hematoxylin. Sections in which the primary antibody was omitted served as negative control.
Six digital images of each case were captured with a digital micro camera (JVC TK-1270/RGB; Tokyo, Japan) at ϫ400 magnification interfaced with a computer. Total and positive-staining cells were identified within the digitalized images by means of the software Image Tool 3.0 (University of Texas Health Science Center, San Antonio, TX, USA). Both parafibromin and cyclin D1 staining were evaluated in the nucleus regardless of staining intensity. 22 Indexes of labeled cells for parafibromin and cyclin D1 were obtained by dividing the positive cells by the total number of tumor cells and multiplying by 100.
RNA extraction, complementary DNA synthesis, and mutational screening of the HRPT2 transcript Total RNA was extracted from 6 FD, 9 OF, and 2 OS freshly obtained samples, as well as from 7 normal jaw bone samples, applying Trizol reagent according to the manufacturer's recommended protocol (Invitrogen, Carlsbad, CA, USA). Total RNA was treated with DNase, and the reverse transcription of 1 g RNA to complementary DNA (cDNA) was performed with the use of Superscript III First-Strand (Invitrogen) following the manufacturer's instructions.
The transcript sequence of HRPT2 was amplified and sequenced from the tumor cDNA obtained from patients with FD (n ϭ 3), OF (n ϭ 8), and OS (n ϭ 2) (Table I) . cDNA was used as a template for the PCR amplification of the full-length transcript of the human HRPT2 cDNA, using primers previously described. 29 The GenBank accession number NM_024529.3 was used as a reference sequence (nucleotide ϩ 1 corresponds to the A of the ATG-translation initiation codon). ␤-Actin cDNA was amplified as an internal control. The amplified products were electrophoresed on a 1.5% agarose gel, purified with the use of the GFX PCR DNA and Gel Band Purification Kit (Amersham Biosciences, Piscataway, NJ, USA), and sequenced on the ABI Prism 310 Genetic Analyzer (Applied Biosystems).
Quantitative reverse-transcription PCR
For quantitative PCR (qPCR) analyses, wild-type transcripts of the HRPT2 and Cyclin D1 cDNA were detected with 1ϫ Sybr Green PCR Master Mix (Applied Biosystems, Warrington, UK). Samples included in the qPCR assay are listed in Table I . Reaction conditions were as previously described.
30 HRPT2 and Cyclin D1 primers were designed with the use of the Primer Express software (Applied Biosystems, Foster City, CA, USA), version 3.0, yielding PCR products of 116 bp (Cyclin D1) and 126 bp (HRPT2). The primer sequences were HRPT2 F5=GCCAACCCAGAGAGT-ACTACACATT3= and R5=GATCAGGTCTTCTAAC-CACAGGAATAT3= and Cyclin D1 F5=TGAGGA-GCCCCAACAACTT3= and R5=CAGCAGGGCTTC-GATCTG3=. Data were presented as the relative quantity of a target gene normalized to endogenous ␤-actin and relative to a calibrator sample (reference), i.e., relative quantification (RQ). Relative quantification of these genes expressions was calculated with the 2 Ϫ⌬⌬Ct method. As a calibrator, a pool of normal mucosa samples was included. As controls, normal bone samples were included (from a total of 7, only 2 resulted in good quality RNA extraction and cDNA synthesis).
Statistical analysis
Mann-Whitney, Spearman correlation, and Fisher exact tests were used. All statistical analyses were carried out Cases 7, 9, 10, and 11 were previously reported. 22 We could not extract normal DNA from cases 2 and 12 and so they were not included in the loss of heterozygosity (LOH) analyses. Case 16 was included only in the LOH assay. Cases 19 and 20 were included only in the immunohistochemistry (IHC) and LOH analyses. qPCR results are represented in RQ (relative quantification). het, heterozygous; hom, homozygous; other abbreviations as in Table I with the use of the SPSS 17.0 software program, and probability values of Ͻ.05 were considered to be statistically significant.
RESULTS
The results of molecular analyses (LOH, IHC, mRNA transcription, and sequencing) and the main clinical characteristics of all fresh sample lesions are presented in Tables I and II. Five samples of FD, 9 OF, and 4 OS samples then underwent microsatellite analyses (Table I) . Eleven informative samples, (i.e., heterzygous) exhibited LOH at the HRPT2 locus: 3/5 FD samples, 6/9 OF samples, and 2/2 OS cases (Table II) . Representative results of LOH in the region 1q25.3 at the HRPT2 gene locus are depicted in Figure 2 .
The overall IHC results are displayed in Figure 3 , and the immunostaining pattern of parafibromin and cyclin D1 are shown in Figure 4 . Parafibromin and cyclin D1 staining were identified almost exclusively in the nucleus. Although all of the 41 lesions evaluated showed strong parafibromin positivity, only 9 of them showed cyclin D1 positivity (including 3 OF, 4 FD, and 2 OS). Although OF lesions expressed more parafibromin protein than OS (P Ͻ .05; Mann-Whitney test), no statistically significant differences could be observed among the 3 groups of lesions in cyclin D1 immunoexpression (P Ͼ .05; Mann-Whitney test). No correlation was noted between parafibromin and cyclin D1 protein immunostaining (P Ͼ .05; Spearman correlation test).
Direct sequencing of all coding regions of the HRPT2 gene at the cDNA level was performed in 3 FD, 8 OF, and 2 OS fresh tumor samples (Table I) . Only 1 OF harbored an inactivating mutation in exon 1 (c.70delG), which predicts a premature truncation of parafibromin at codon 25 ( Figure 5 ). This mutation was detected in both primary (case 7) and recurrent samples (case 8). DNA of this same primary tumor was previously sequenced and demonstrated the same mutation, which was not detected in germline DNA. 22 This primary sample also revealed a large deletion (from codon 415 to codon 440) in transcript encoded by exons 14-15 c1245del GGGCACTGCAATTAGTGTTACAGTAC-CTTATAGAGTAGTAGACCAGCCCCTTAAACTT-ATGCCTCAAGACTGGGA that could not be detected in the sample of the recurrent tumor. We did not find mutations in the HPT-JT OF sample (case 11) that had previously shown a heterozygous germline DNA mutation, 22 even after repeated sequencing and PCR with 2 distinct tumor portions.
Results of relative quantification of HRPT2 and Cyclin D1 mRNAs are presented in Table I and displayed in Figure 6 . The 2 normal bone fragments expressed ␤-actin but did not express either HRPT2 or cyclin D1 transcripts. All samples expressed more cyclin D1 than did the normal mucosa. One FD (case 5) and 1 OS (case 18) did not show HRPT2 mRNA transcription. The transcriptional levels of Cyclin D1 and HRPT2 were similar in the 3 groups of lesions. (P Ͼ .05; Mann-Whitney test.)
Overall, HRPT2 mRNA expression was not different in the group of lesions displaying HRPT2-linked marker LOH compared with the group of lesions that exhibited no allelic loss at the HRPT2 locus. The 2 samples that did not express HRPT2 mRNA [cases 5 (FD) and 18 (OS)], both had evidence of LOH albeit with different markers. Yet in both these lesions, almost 100% of the tumor cells expressed parafibromin as assessed by IHC. 
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The samples that expressed very low levels of HRPT2 mRNA (expressed less than the calibrator) were cases 1 and 3 (FD) and 10 (juvenile OF). Cases 1 and 10 showed LOH at the HRPT2 locus, whereas case 3 did not. All 3 samples showed positive parafibromin immunostaining for 85%-100% and showed no sequence alteration of the HRPT2 cDNA.
The sample representing an OF recurrence (case 8) revealed LOH using both markers, whereas the primary lesion (case 7) did not show LOH. The recurrent lesion showed decreased transcriptional levels and immunoexpression of HRPT2/parafibromin in addition to increased Cyclin D1 transcription compared with the primary lesion of the same patient.
DISCUSSION
The present study assessing the involvement of the HRPT2 gene in the pathogenesis of 3 bone lesions in the maxillomandibular region, shows that despite the frequent allelic loss at the HRPT2 locus in these lesions, this finding did not correlate with either somatic mutations or a discernible effect on mRNA or protein OOOO ORIGINAL ARTICLE Volume 115, Number 3 expression of HRPT2 in the majority of tumors analyzed. One plausible but speculative explanation is that the allelic loss detected herein targets another tumor suppressor gene that resides within the same chromosomal region. Interestingly, there are other tumor suppressor candidate genes located at the same genetic locus, 1q25, such as RNASEL, which are involved in regulation of cell proliferation and apoptosis. 31 Another candidate to be targeted by the LOH is GLRX2, which was previously associated with cellular differentiation and transformation, possibly with a role in tumor progression in lung cancer 32 and in melanoma cell lines. 33 Moreover, a previous publication showed a germline mutation in an HPT-JT family affecting the whole HRPT2 gene and including other genes closely related to HRPT2, such as TROVE2 and GLRX2. 34 Therefore, we can speculate that these genes are also possible targets of LOH.
In the present study, even when somatic inactivating mutations in the HRPT2 gene were found in the primary and recurrent tumors from a single individual, and 1 of the 2 tumors also showed allelic loss, these lesions expressed normal parafibromin protein as assessed by IHC. This may be the result of tumor heterogeneity, where different clones exist in the same tumor: In some clones, HRPT2 is inactivated, and in others HRPT2 expression is maintained because these clones lack the inactivating mutation. It may also indicate that HRPT2 inactivation is not an early event that drives the initiation of tumorigenesis in this tumor type but is rather a progression-promoting event. However, firm conclusions can not be drawn based on this single case.
In cell culture models, parafibromin showed antiproliferative properties and the ability to inhibit cyclin D1 expression, 16, 35 suggesting an obvious model for neoplasia resulting from the loss of the parafibromin function. An interesting finding was that the recurrent OF showed decreased transcriptional levels and immunoexpression of HRPT2/parafibromin in addition to increased Cyclin D1 transcription compared with its primary counterpart. This recurrent lesion presented LOH at the HRPT2 locus. However, such a clear relation between HRPT2 and cyclin D1 expression could not be drawn for the other lesions. Therefore, it is not clear if cyclin D1 regulation results from a direct or indirect action of parafibromin in the subset of bone lesions included in our study. Further work on parafibromin and cyclin D1 and their integration with other regulatory pathways will clarify their precise role in transcriptional regulation and the pathogenesis of these bone lesions.
There is a paucity of data published on the molecular mechanisms underlying these jaw bone lesions. Notably, 1 case of OF has been published that described somatic mutation of the HRPT2 gene (same case included in this study) and a second case presented a germline mutation. 22 Therefore, from the currently available data, we can conclude that the contribution of HRPT2 gene inactivation to the pathogenesis of OF, FD, and OS is marginal at best and may be limited to the progression of the tumor rather than its initiation.
